|
Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Advaxis (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Genmab (Inst); Immunogen (Inst); Millennium (Inst); MSD Belgium (Inst); Oncoinvent (Inst); PharmaMar (Inst); Roche (Inst); Roche (Inst); Sotio (Inst); Tesaro (Inst) |
Research Funding - Amgen (Inst); Genmab (Inst); Oncoinvent (Inst); Roche (Inst); Stichting tegen kanker (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Genmab; PharmaMar; Roche; Takeda; Tesaro |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Eisai; Ipsen; Novartis |
Consulting or Advisory Role - Eisai; Ipsen; Novartis |
Research Funding - Advanced Accelerator Applications; Eisai; Exelixis; Ipsen; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Novartis (Inst); PharmaMar (Inst) |
Travel, Accommodations, Expenses - MSD; Roche |
|
|
No Relationships to Disclose |